Medicines planning
48 results
Applied filters
Annual medicines planning publication, Prescribing Outlook
12 January 2026Our annual output to support managed entry and budget planning for new medicines, new indications and patent expiries in the NHS.
Preparing to use golimumab biosimilar
9 January 2026One golimumab biosimilar (Gobivaz) is available. We offer general information and implementation advice.
New Product Evaluations
22 December 2025A list of new product evaluations that are freely available to NHS staff.
Biosimilar and key generic medicines – December 2025 update
10 December 2025An update about biosimilar and key generic medicines to support system planning and mobilisation.
The licence and supporting evidence for golimumab biosimilar
28 November 2025We highlight evidence for licensed golimumab biosimilar(s) and differences between the biosimilar(s) and the reference product (Simponi).
Preparing to use ranibizumab biosimilar
5 November 2025Ranibizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team
The licence and supporting evidence for ranibizumab biosimilars
5 November 2025Four licensed ranibizumab biosimilars are available: Byooviz, Ongavia, Rimmyrah and Ximluci. Learn about the licensed indications and supporting evidence
Primary care discussions: biosimilar insulin
30 September 2025Discussion about the considerations of implementing biosimilar insulin in primary care. Hints and tips for systems considering a move to biosimilar insulin.
Understanding biosimilar and generic market entry
12 September 2025New medicines have several protections against competition. Other factors influence availability of biosimilars or generics after loss of exclusivity.
Biosimilar and key generic medicines – September 2025 update
11 September 2025An update about biosimilar and key generic medicines to support system mobilisation.